CN104496922A - 腈基苯二烯四氮唑类化合物、其制备方法和用途 - Google Patents
腈基苯二烯四氮唑类化合物、其制备方法和用途 Download PDFInfo
- Publication number
- CN104496922A CN104496922A CN201510016201.5A CN201510016201A CN104496922A CN 104496922 A CN104496922 A CN 104496922A CN 201510016201 A CN201510016201 A CN 201510016201A CN 104496922 A CN104496922 A CN 104496922A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- application
- nitrile
- grouping
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 title abstract description 10
- -1 benzene diene tetrazole compound Chemical class 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 8
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 230000001732 thrombotic effect Effects 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 abstract description 15
- 229940098892 Protease-activated receptor-1 antagonist Drugs 0.000 abstract description 5
- 239000005557 antagonist Substances 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000002596 correlated effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- 238000003756 stirring Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 210000001772 blood platelet Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102100037136 Proteinase-activated receptor 1 Human genes 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 101710121440 Proteinase-activated receptor 1 Proteins 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 0 *CC=CC=Cc(cccc1)c1C#N Chemical compound *CC=CC=Cc(cccc1)c1C#N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 108010070519 PAR-1 Receptor Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000002020 Protease-activated receptors Human genes 0.000 description 2
- 108050009310 Protease-activated receptors Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000003790 Thrombin receptors Human genes 0.000 description 2
- 108090000166 Thrombin receptors Proteins 0.000 description 2
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000002560 nitrile group Chemical group 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- HHDRWGJJZGJSGZ-UHFFFAOYSA-N C(c1n[nH]nn1)c1ccccc1 Chemical compound C(c1n[nH]nn1)c1ccccc1 HHDRWGJJZGJSGZ-UHFFFAOYSA-N 0.000 description 1
- CGYBTPXBQNJVNW-YLDLMLGBSA-N CCOC(/C=C/C=C/c(cccc1)c1C#N)=O Chemical compound CCOC(/C=C/C=C/c(cccc1)c1C#N)=O CGYBTPXBQNJVNW-YLDLMLGBSA-N 0.000 description 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- LYKBDCDJDWPDAB-IJIVKGSJSA-N N#Cc1ccccc1/C=C/C=C/CO Chemical compound N#Cc1ccccc1/C=C/C=C/CO LYKBDCDJDWPDAB-IJIVKGSJSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000032626 PAR-1 Receptor Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000007466 Purinergic P2 Receptors Human genes 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
化合物 | 血小板凝聚的抑制IC50(μM) |
I-1 | 1.17 |
I-2 | 0.22 |
I-3 | 0.46 |
I-4 | 0.61 |
I-5 | 0.29 |
I-6 | 0.85 |
I-7 | 1.30 |
I-8 | 1.51 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510016201.5A CN104496922B (zh) | 2015-01-13 | 2015-01-13 | 腈基苯二烯四氮唑类化合物、其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510016201.5A CN104496922B (zh) | 2015-01-13 | 2015-01-13 | 腈基苯二烯四氮唑类化合物、其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104496922A true CN104496922A (zh) | 2015-04-08 |
CN104496922B CN104496922B (zh) | 2016-04-06 |
Family
ID=52938396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510016201.5A Active CN104496922B (zh) | 2015-01-13 | 2015-01-13 | 腈基苯二烯四氮唑类化合物、其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104496922B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101472907A (zh) * | 2006-06-19 | 2009-07-01 | 皮埃尔法布雷医药公司 | 肉桂酰基-哌嗪衍生物及其作为par-1拮抗剂的用途 |
WO2012040636A2 (en) * | 2010-09-24 | 2012-03-29 | The Broad Institute, Inc. | Compounds and methods for treating diseases mediated by protease activated receptors |
CN104072436A (zh) * | 2014-07-23 | 2014-10-01 | 张远强 | 对位取代的四氮唑苯乙酮化合物、其制备方法和用途 |
-
2015
- 2015-01-13 CN CN201510016201.5A patent/CN104496922B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101472907A (zh) * | 2006-06-19 | 2009-07-01 | 皮埃尔法布雷医药公司 | 肉桂酰基-哌嗪衍生物及其作为par-1拮抗剂的用途 |
WO2012040636A2 (en) * | 2010-09-24 | 2012-03-29 | The Broad Institute, Inc. | Compounds and methods for treating diseases mediated by protease activated receptors |
CN104072436A (zh) * | 2014-07-23 | 2014-10-01 | 张远强 | 对位取代的四氮唑苯乙酮化合物、其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN104496922B (zh) | 2016-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104529927B (zh) | 一类含卤代苯的恶二唑亚砜化合物、其制备方法和用途 | |
CN104098520A (zh) | 苯基三唑希夫碱类化合物、其制备方法和用途 | |
CN104086503B (zh) | Par-1拮抗剂及其用途 | |
CN104496922B (zh) | 腈基苯二烯四氮唑类化合物、其制备方法和用途 | |
CN104496924B (zh) | 卤苯二烯四氮唑类化合物、其制备方法和用途 | |
CN104496923B (zh) | 硝基苯二烯四氮唑类化合物、其制备方法和用途 | |
CN104496927B (zh) | 二烯四氮唑卤苯类化合物、其制备方法和用途 | |
CN104496925B (zh) | 二烯四氮唑类化合物、其制备方法和用途 | |
CN104478819B (zh) | 二烯四氮唑苯胺类化合物、其制备方法和用途 | |
CN104529923B (zh) | 二烯四氮唑硝基苯类化合物、其制备方法和用途 | |
CN104496926B (zh) | 一类含二烯四氮唑结构的化合物、其制备方法和用途 | |
CN104610184A (zh) | 苯二烯四氮唑类化合物、其制备方法和用途 | |
CN104513212B (zh) | 一类含硝基苯的恶二唑亚砜化合物、其制备方法和用途 | |
CN104529931B (zh) | 一类含烷氧对位取代苯的恶二唑亚砜化合物、其制备方法和用途 | |
CN104529929B (zh) | 含烷氧取代苯的恶二唑亚砜化合物、其制备方法和用途 | |
CN104529930B (zh) | 一类含腈基苯的噁二唑亚砜化合物、其制备方法和用途 | |
CN104072432A (zh) | 含苯基取代三唑希夫碱类结构的化合物、其制备方法和用途 | |
CN104086495A (zh) | 末端双取代的三唑希夫碱结构化合物、其制备方法和用途 | |
CN104356059A (zh) | 含卤代吡啶基的反式环己烷酰胺类化合物及用途 | |
CN104356093A (zh) | 含卤代苯基的反式环己烷酰胺类化合物和用途 | |
CN104356058A (zh) | 含烷氧基吡啶的反式环己烷酰胺类化合物及用途 | |
CN104356094A (zh) | 反式环己烷酰胺类化合物、其制备方法和在医药上的用途 | |
CN104356095A (zh) | 烷氧基苯基取代的反式环己烷酰胺类化合物和用途 | |
CN104496932A (zh) | 一类含胺基对位取代苯的恶二唑亚砜化合物、其制备方法和用途 | |
CN104529928A (zh) | 一类恶二唑亚砜化合物、其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Nitrile-grouping benzene diene tetrazole compound and preparation method and application thereof Effective date of registration: 20170816 Granted publication date: 20160406 Pledgee: Guangdong Nanhai Rural Commercial Bank branch branch of Limited by Share Ltd. Pledgor: FOSHAN SAIWEISI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Registration number: 2017990000756 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190604 Granted publication date: 20160406 Pledgee: Guangdong Nanhai Rural Commercial Bank branch branch of Limited by Share Ltd. Pledgor: FOSHAN SAIWEISI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Registration number: 2017990000756 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191021 Address after: Jiaxing City, Zhejiang province 314500 Tongxiang Tongxiang City Economic Development Zone high-tech West Road No. 518 Patentee after: HONGGUAN BIO-PHARMA Co.,Ltd. Address before: Chancheng district has 528000 Taiwan public in Guangdong province Foshan City No. 32 first floor 1636, shop No. 1637 Patentee before: FOSHAN SAIWEISI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Nitrile benzenediene tetrazolium compound, its preparation method and use Effective date of registration: 20220831 Granted publication date: 20160406 Pledgee: Bank of Hangzhou Limited by Share Ltd. Tongxiang branch Pledgor: HONGGUAN BIO-PHARMA Co.,Ltd. Registration number: Y2022330001992 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20160406 Pledgee: Bank of Hangzhou Limited by Share Ltd. Tongxiang branch Pledgor: HONGGUAN BIO-PHARMA Co.,Ltd. Registration number: Y2022330001992 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |